Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning
-
Published:2024-08-28
Issue:
Volume:
Page:
-
ISSN:0007-0920
-
Container-title:British Journal of Cancer
-
language:en
-
Short-container-title:Br J Cancer
Author:
Kawai MunenoriORCID, Fukuda AkihisaORCID, Otomo Ryo, Obata Shunsuke, Minaga Kosuke, Asada Masanori, Umemura Atsushi, Uenoyama Yoshito, Hieda Nobuhiro, Morita Toshihiro, Minami Ryuki, Marui Saiko, Yamauchi Yuki, Nakai Yoshitaka, Takada Yutaka, Ikuta Kozo, Yoshioka Takuto, Mizukoshi Kenta, Iwane Kosuke, Yamakawa Go, Namikawa Mio, Sono Makoto, Nagao Munemasa, Maruno Takahisa, Nakanishi YukiORCID, Hirai Mitsuharu, Kanda Naoki, Shio Seiji, Itani Toshinao, Fujii Shigehiko, Kimura Toshiyuki, Matsumura Kazuyoshi, Ohana Masaya, Yazumi Shujiro, Kawanami Chiharu, Yamashita Yukitaka, Marusawa Hiroyuki, Watanabe Tomohiro, Ito Yoshito, Kudo Masatoshi, Seno Hiroshi
Abstract
Abstract
Background
Pancreatic cancer is often diagnosed at advanced stages, and early-stage diagnosis of pancreatic cancer is difficult because of nonspecific symptoms and lack of available biomarkers.
Methods
We performed comprehensive serum miRNA sequencing of 212 pancreatic cancer patient samples from 14 hospitals and 213 non-cancerous healthy control samples. We randomly classified the pancreatic cancer and control samples into two cohorts: a training cohort (N = 185) and a validation cohort (N = 240). We created ensemble models that combined automated machine learning with 100 highly expressed miRNAs and their combination with CA19-9 and validated the performance of the models in the independent validation cohort.
Results
The diagnostic model with the combination of the 100 highly expressed miRNAs and CA19-9 could discriminate pancreatic cancer from non-cancer healthy control with high accuracy (area under the curve (AUC), 0.99; sensitivity, 90%; specificity, 98%). We validated high diagnostic accuracy in an independent asymptomatic early-stage (stage 0-I) pancreatic cancer cohort (AUC:0.97; sensitivity, 67%; specificity, 98%).
Conclusions
We demonstrate that the 100 highly expressed miRNAs and their combination with CA19-9 could be biomarkers for the specific and early detection of pancreatic cancer.
Funder
Japan Agency for Medical Research and Development MEXT | Japan Society for the Promotion of Science MEXT | Japan Science and Technology Agency
Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21. 2. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. 3. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605–17. 4. Park W, Chawla A, O’Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326:851–62. 5. Egawa S, Toma H, Ohigashi H, Okusaka T, Nakao A, Hatori T et al. Japan Pancreatic Cancer Registry; 30th Year Anniversary Japan Pancreas Society. 2012 www.pancreasjournal.com.
|
|